Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Boill Healthcare Holdings Limited 保集健康控股有限公司

(Incorporated in Cayman Islands with limited liability)
(Stock Code: 1246)

FURTHER CLARIFICATION AND SUPPLEMENTAL ANNOUNCEMENT AND RE-DESIGNATION OF CHAIRMAN OF THE BOARD

Reference is made to (i) the announcement of Boill Healthcare Holdings Limited (the "Company") dated 22 July 2024 in relation to the change of directors of the Company and change in composition of board committees and the relevant updated list of directors and their roles and functions (the "Change of Directors Announcement"); and the announcement of the Company dated 24 July 2024 in relation to the clarification regarding to the Change of Directors Announcement (the "Clarification Announcement") (collectively, the "Announcements"). Capitalised terms used in this announcement shall have the same meanings as those defined in the Announcements, unless stated otherwise.

FURTHER CLARIFICATION

The Board wishes to clarify that:

- (i) The Board has received the resignation letters from each of Mr. Zhang Sheng Hai, Mr. Wang Zhe and Mr. Yi Baxian as the Directors, and have been reviewed and approved by the Board;
- (ii) The Board and the Nomination Committee have been reviewed and approved the appointment of Mr. He, Ms. Mak, Mr. Chan and the Mr. Liang;
- (iii) the Change of Directors Announcement was released with Board's approval;
- (iv) none of (i) the removal of Company Secretary, (ii) the cessation of Authorised Representative, and Process Agent, and (iii) change of principal place of business in Hong Kong as set out in the Clarification Announcement have been reviewed or approved by the Board; and
- (v) there had been no change of Mr. Yuen Wai Keung as Company Secretary, Authorised Representative and Process Agent; and the principal place of business of the Company remains

SUPPLEMENTAL TO CHANGE OF DIRECTORS ANNOUNCEMENT

In addition to the information contained in the Change of Directors Announcement, the Board would like to provide supplemental information on the appointment of Ms. Mak, Mr. Chan and Mr. Liang.

- (a) Ms. Mak, Mr. Chan and Mr. Liang have confirmed (i) their independence as regards each of the factors referred to in Rule 3.13(1) to (8) of the Listing Rules; (ii) that they have no past or present financial or other interest in the business of the Group or any connection with any core connected person (as defined in the Listing Rules) of the Company; and (iii) that there are no other factors that may affect their independence at the time of their appointment.
- (b) Mr. Liang was an executive director of Alco Holdings Limited the shares of which are listed on the Main Board of the stock Exchange (stock code: 328) from 9 October 2023 to 8 April 2024. Save as disclosed above and the Change of Directors Announcement, there is no other information required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules, and there is no other matter in relation to the appointment of Mr. Liang that needs to be brought to the attention of the shareholders of the Company.

The above supplemental information does not affect other information contained in the Change of Directors Announcement.

RE-DESIGNATION OF CHAIRMAN OF THE BOARD

The Board hereby announces that with effect from 24 July 2024:

- (i) Mr. Qiu Dongfang has ceased to act as the chairman (the "Chairman") of the Board but remains as an executive Director; and
- (ii) Mr. He Yu, and executive Director, has taken up the position as the Chairman.

Biographical detail of Mr. He

Mr. He, aged 32, was appointed as an executive Director on 22 July 2024. He graduated from ChenZhou Vocational Technical College in July 2022 with diploma of electromechanical integration technology. Mr. He was employed by an investment company as a manager and was mainly responsible for managing and reviewing projects. From October 2021 to March 2023, Mr. He worked as operations director for a business development company and was mainly responsible for overseeing the company's daily operations and formulating its strategic direction.

Mr. He has entered into a service contract with the Company, unless terminated by either party in accordance with the terms thereof and subject to retirement by rotation and re-election at the annual general meeting of the Company at least once every three years in accordance with the articles of association of the Company. He is entitled to a basic salary of HK\$180,000 per annum, which was determined by the Board on the recommendation of the Remuneration Committee with reference to his qualifications, experience, duties and responsibilities, as well as the prevailing market conditions.

Save as disclosed above and as confirmed by Mr. He, Mr. He does not hold any directorships in any listed public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years prior to the date of this announcement or any other position with the Company and other members of the Group or other major appointments and professional qualifications and does not have any relationships with any Directors, senior management or substantial or controlling shareholders (having the meaning ascribed to it in the Listing Rules) of the Company, nor any interest in the shares of the Company which are required to be disclosed pursuant to Part XV of the SFO, as at the date of this announcement.

Save as disclosed above, Mr. He confirmed that there is no other information which is discloseable pursuant to the requirements under Rules 13.51(2)(h) to (v) of the Listing Rules and there are no other matters that need to be brought to the attention of the shareholder of the Company.

By Order of the Board

Boill Healthcare Holdings Limited

He Yu

Executive Director and Chairman

Hong Kong, 24 July 2024

As at the date of this announcement and after the above appointments and resignations, the Company has (i) two executive Directors, namely Mr. Qiu Dongfang and Mr. He Yu; (ii) one non-executive Director, namely Mr. Chui Kwong Kau; and (iii) four independent non-executive Directors, namely Ms. Tang Man Yi, Ms. Mak Suet Man, Mr. Chan Chi Hang and Mr. Liang Yanan.